T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W Lee(Maryland Oncology Hematology), James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui(Maryland Oncology Hematology), Cindy Delbrook(Maryland Oncology Hematology), Steven A. Feldman, Terry J. Fry(Maryland Oncology Hematology), Rimas J. Orentas(Maryland Oncology Hematology), Marianna Sabatino(National Institutes of Health), Nirali N. Shah(Maryland Oncology Hematology), Seth M. Steinberg(Office of the Director), D. Stroncek(National Institutes of Health), Nick Tschernia(National Institutes of Health), Constance M. Yuan, Hua Zhang(Maryland Oncology Hematology), Ling Zhang(Maryland Oncology Hematology), Steven A. Rosenberg, Alan S. Wayne(University of Southern California), Crystal L. Mackall(National Institutes of Health)
The Lancet
October 13, 2014
10.1016/s0140-6736(14)61403-3
Cited by 2,935

Abstract

Related Papers

C-reactive protein: a critical update
Mark B. Pepys, Gideon M. Hirschfield|Journal of Clinical Investigation|2003|3.5k
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee, Rebecca Gardner, David Porter et al.|Blood|2014|2.8k
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan, James C. Yang, Mio Kitano et al.|Molecular Therapy|2010|2.5k
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman et al.|Blood|2011|1.4k
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik et al.|Blood|2010|1.3k